Evidence map›Paper›PMID 39031929›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024

Assessing the efficacy of mesotherapy products: Ultra Exo Booster, and Ultra S Line Plus in hair growth: An ex vivo study.

Shu Yi Zhou, Nguyen Ngan Giang, Hyunjee Kim, Pham Ngoc Chien, Linh Thi Thuy Le, Thuy-Tien Thi Trinh, Pham Thi Nga, Han Jin Kwon, Jung Ryul Ham, Won Ku Lee and 5 more

Abstract read
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Assessing the efficacy of mesotherapy products: Ultra Exo Booster, and Ultra S Line Plus in hair growth: An ex vivo study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shu Yi ZhouDepartment of Medicine, College of Medicine, Seoul National University, Seoul, South Korea.
Nguyen Ngan GiangDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Hyunjee KimKorean Institute of Nonclinical Study, H&Bio. Co. Ltd., Seongnam, South Korea.
Pham Ngoc ChienDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Linh Thi Thuy LeDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Thuy-Tien Thi TrinhDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Pham Thi NgaDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Han Jin KwonUltraV Co., Ltd. R&D Center, Seoul, South Korea.
Jung Ryul HamUltraV Co., Ltd. R&D Center, Seoul, South Korea.
Won Ku LeeUltraV Co., Ltd. R&D Center, Seoul, South Korea.
Yeon Ju GuUltraV Co., Ltd. R&D Center, Seoul, South Korea.
Xin Rui ZhangDepartment of Medicine, College of Medicine, Seoul National University, Seoul, South Korea.
Yong Xun JinDepartment of Medicine, College of Medicine, Seoul National University, Seoul, South Korea.
Sun Young NamDepartment of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Chan Yeong HeoDepartment of Medicine, College of Medicine, Seoul National University, Seoul, South Korea.ORCID https://orcid.org/0000-0001-9003-7365

Funding

Ministry of Trade, Industry and Energy 20022874UltraV
6 · The paper itself

Abstract

In this study, scalp tissues from Korean adults between 20 and 80 without skin disease were used. Scalp tissues were processed, and hair follicles were isolated and cultured with different treatments (including Bioscalp, Ultra Exo Booster, and Ultra S Line Plus) from Ultra V company. Over 12 days, observations and measurements of hair follicle characteristics were recorded at intervals (Days 0, 3, 6, 9, and 12). The study assessed the impact of these substances on hair follicle growth and morphology. Bioscalp, combined with Ultra Exo Booster and Ultra S Line Plus, showed significant hair elongation in ex vivo. Preservation of hair bulb diameter was observed, indicating potential for sustained hair growth by exosome-based products. The hair growth cycle analysis suggested a lower transition to the catagen stage in test products from Ultra V compared to non-treated groups. The research findings indicated that the tested formulations, especially the combination of Bioscalp, Ultra Exo Booster, and Ultra S Line Plus, demonstrated significant effectiveness in promoting hair growth, maintaining the integrity of the hair bulb, and reducing the transition to the catagen stage. The study suggests promising alternative treatments for hair loss, illustrating results that were as good as those of the conventional testing product groups.

Indexed as

HairHair FollicleMesotherapyScalpAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung Adultex vivohairgrowthhairlossmesotherapy

Identifiers

PMID39031929
PMCPMC11259544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.